CTNS

If you or a family member has unexplained kidney trouble that started young, eye crystals, growth problems, or a confirmed diagnosis of cystinosis somewhere in the family tree, this is the test that gives you a definitive molecular answer. CTNS sequencing identifies the genetic changes that cause cystinosis, a rare but treatable disease where cellular waste builds up because one specific protein cannot do its job.

Knowing your CTNS status matters because early treatment with cysteamine substantially changes the trajectory of this disease. The test also clarifies confusing cases, especially milder juvenile or adult-onset forms where standard markers can look almost normal and the diagnosis is easy to miss.

What CTNS Actually Codes For

CTNS (the abbreviation stands for cystinosin, lysosomal cystine transporter) sits on chromosome 17 and provides instructions for a protein called cystinosin. Cystinosin lives in the membrane of the lysosome, the small waste-processing compartment inside every cell. Its job is to pump the amino acid cystine out of the lysosome and back into the rest of the cell, paired with hydrogen ions, so cystine does not accumulate.

When both copies of CTNS carry damaging changes, cystinosin either fails to form or cannot move cystine properly. Cystine then accumulates inside lysosomes, eventually forming crystals that damage cells across many organs. Cystinosin also turns up in melanosomes, the pigment-producing compartments of skin and hair cells, which is why people with cystinosis often have noticeably fair hair and altered pigmentation.

Why a Genetic Answer Matters

Cystinosis is inherited in an autosomal recessive pattern, meaning two faulty CTNS copies are required for the disease to appear. A person with only one faulty copy is a carrier and is generally healthy. CTNS sequencing distinguishes between people who are affected, carriers, and those with two normal copies. That distinction directly informs treatment, family planning, and screening of relatives.

Within affected people, the type of CTNS change predicts how severe the disease will be. Truncating deletions or severe missense changes that abolish or markedly reduce cystinosin transport produce the classic infantile form, which presents with kidney Fanconi syndrome (a leak of salts, sugars, and proteins into the urine) and progresses to kidney failure in childhood without treatment. Milder in-frame or missense variants in less critical regions can leave some cystinosin function intact and are linked to juvenile or late-onset disease, where people may not present until adolescence or adulthood.

Kidney Disease

The kidney is the organ that suffers first and most visibly in cystinosis. Defective CTNS causes a syndrome where the kidney's filtering tubes leak salts, glucose, amino acids, and small proteins, leading to dehydration, poor growth, and electrolyte problems. Without cysteamine treatment, kidney function declines steadily toward end-stage kidney disease, typically in childhood in the classic infantile form.

Juvenile and late-onset cases often present more subtly, with proteinuria, partial Fanconi syndrome, or kidney decline appearing in adolescence or adulthood. People in these milder categories almost always carry at least one less-damaging CTNS variant. In an international cohort of 453 people with cystinosis followed across five decades, earlier diagnosis and earlier start of cysteamine therapy substantially improved kidney survival and growth, and CTNS genotype had less impact on kidney outcome in treated groups than the timing of treatment did.

Eye and Vision Effects

Cystine crystals deposit in the cornea, where they are visible on a slit-lamp eye exam and contribute to light sensitivity, glare, and discomfort. In milder ocular-only cystinosis, eye involvement may be the dominant or only obvious feature, and CTNS sequencing is often required to confirm the diagnosis when biochemical testing is borderline.

Other Organ Effects

Cystinosin is needed in more than just the kidney. People with cystinosis can develop thyroid hormone deficiency, problems with insulin and other endocrine hormones, reduced testicular function in men, neurological and sensory changes including measurable differences in visual and auditory processing, and altered hair and skin pigment composition. In a study of males with infantile nephropathic cystinosis, semen analysis showed enough preserved sperm production that cryostorage was a realistic option for about 20% of young men, and surgical sperm retrieval offered additional chances at biological fatherhood.

How CTNS Variants Cluster By Population

What this means for you: if you have ancestry from any of these regions and a family history of cystinosis or unexplained childhood kidney failure, targeted CTNS testing has a high chance of identifying the responsible variant. In an analysis of affected individuals of German and Swiss origin, CTNS sequencing identified the disease-causing variant on the large majority of tested alleles, supporting CTNS analysis as a standard diagnostic test in this setting.

How CTNS Testing Fits Alongside Cystine Measurement

The biochemical gold standard for diagnosing cystinosis is measuring cystine inside white blood cells, which is markedly elevated in classic disease. CTNS sequencing complements this measurement and is essential when the cystine result is ambiguous. In a documented case of juvenile cystinosis, white blood cell cystine was only slightly raised, and the diagnosis was confirmed only by CTNS sequencing combined with cystine measurement in slow-dividing cells. Missing this delays cysteamine treatment, which is the entire point of catching the disease early.

Newborn Screening and Early Detection

Because early cysteamine treatment changes outcomes so dramatically, genetic newborn screening for cystinosis has become technically feasible. In a high-throughput program that screened newborns in a high-prevalence region, a qPCR test targeting common CTNS variants combined with next-generation sequencing detected affected newborns with high sensitivity. This is the type of early molecular detection that lets families start treatment before significant kidney damage has occurred.

Why Re-Testing Is Usually Not the Question

CTNS sequencing is a one-time genetic test. Your CTNS genotype does not change over your lifetime. What does change is the interpretation: as more variants are catalogued and reclassified, a previously uncertain finding may become clearly disease-causing or clearly benign. If your initial test returned a variant of uncertain significance, it is reasonable to ask for a reinterpretation every few years, especially before major reproductive or treatment decisions, because the supporting evidence in genetic databases grows over time.

What does benefit from regular tracking are the consequences of cystinosis if you are affected: white blood cell cystine levels (to adjust cysteamine), kidney function markers, thyroid hormones, growth, and ophthalmology exams. These should be monitored on the schedule your specialist recommends, typically at least annually and more often during dose adjustments.

What an Unexpected Result Should Prompt You To Do

A positive result identifying two damaging CTNS variants warrants immediate referral to a pediatric or adult nephrologist with experience in cystinosis. The standard workup includes white blood cell cystine measurement, comprehensive kidney function testing including urine protein and electrolytes, a slit-lamp eye exam, thyroid hormone testing, and a discussion of cysteamine therapy. Family members, including children and siblings, should be offered testing because two unaffected parents who each carry one variant have a 25% chance of producing an affected child in each pregnancy.

A single damaging variant identifies you as a carrier. Carriers are generally healthy, but the result is important for reproductive planning: if your partner is also a carrier, your children face a 25% chance of cystinosis. A negative result, with both CTNS copies sequenced and no damaging variants found, makes cystinosis very unlikely, though no genetic test is 100% comprehensive, and clinical suspicion should still be evaluated with biochemical testing.

Emerging Treatment Directions

Beyond cysteamine, gene-directed therapies for cystinosis are entering human trials. An early-phase trial of autologous blood stem cells modified to carry a working CTNS gene in a small number of adults with cystinosis showed acceptable safety, sustained engraftment of the corrected cells, and reduced white blood cell cystine levels over extended follow-up. This is preliminary but suggests a future in which a one-time treatment could substantially reduce the burden of lifelong cysteamine therapy.